These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25556988)

  • 1. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.
    Akshintala S; Marcus L; Warren KE; Murphy RF; Sissung TM; Srivastava A; Goodspeed WJ; Goodwin A; Brewer CC; Zalewski C; King KA; Kim A; Figg WD; Widemann BC
    Pediatr Blood Cancer; 2015 Apr; 62(4):603-10. PubMed ID: 25556988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
    Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
    Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
    J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
    Fox E; Aplenc R; Bagatell R; Chuk MK; Dombi E; Goodspeed W; Goodwin A; Kromplewski M; Jayaprakash N; Marotti M; Brown KH; Wenrich B; Adamson PC; Widemann BC; Balis FM
    J Clin Oncol; 2010 Dec; 28(35):5174-81. PubMed ID: 21060028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
    Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
    Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
    Marcus L; Murphy R; Fox E; McCully C; Cruz R; Warren KE; Meyer T; McNiff E; Balis FM; Widemann BC
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):247-52. PubMed ID: 21706317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Satraplatin: an orally available platinum analog for the treatment of cancer.
    Choy H
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
    Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
    Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
    Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer.
    Cetnar J; Wilding G; McNeel D; LoConte NK; McFarland TA; Eickhoff J; Liu G
    Urol Oncol; 2013 May; 31(4):436-41. PubMed ID: 21481618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).
    Loh ML; Tasian SK; Rabin KR; Brown P; Magoon D; Reid JM; Chen X; Ahern CH; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2015 Oct; 62(10):1717-24. PubMed ID: 25976292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZD0473 pharmacokinetics in Japanese patients: a Phase I dose-escalation study.
    Murakami H; Tamura T; Yamada Y; Yamamoto N; Ueda Y; Shimoyama T; Saijo N
    Eur J Cancer; 2002 Dec; 38 Suppl 8():S1-5. PubMed ID: 12645906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
    Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
    Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.
    McGregor LM; Spunt SL; Furman WL; Stewart CF; Schaiquevich P; Krailo MD; Speights R; Ivy P; Adamson PC; Blaney SM
    Cancer; 2009 Apr; 115(8):1765-75. PubMed ID: 19170226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
    Kim NK; Kim TY; Shin SG; Park YI; Lee JA; Cho YB; Kim KH; Kim DK; Heo DS; Bang YJ
    Cancer; 2001 Apr; 91(8):1549-56. PubMed ID: 11301404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of the oral platinum agent satraplatin in combination with oral vinorelbine in patients with advanced solid malignancies.
    Gallerani E; Cathomas R; Sessa C; Digena T; Bartosek AA; Dal Zotto L; von Moos R
    Onkologie; 2013; 36(1-2):40-5. PubMed ID: 23429330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.